Q-omics provides the consensus-scored FMR1NB profile across patient tissues and cancer cell-line models. FMR1NB expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FMR1NB is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, FMR1NB RNA expression shows 5,915 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where FMR1NB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FMR1NB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FMR1NB survival associations across molecular data types. FMR1NB RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FMR1NB RNA expression–survival associations across cancer types. High FMR1NB expression shows unfavorable associations in KIRC, HNSC, ESCA, KICH and ACC, but favorable associations in COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FMR1NB RNA expression.
This table summarizes FMR1NB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FMR1NB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FMR1NB shows lower tumor expression in LIHC and higher tumor expression in KIRC, THCA, BRCA, KICH and LUSC. The KIRC box plot shows higher FMR1NB RNA expression in tumor versus normal tissue (log2 FC = +0.032, t-test p = .002).
This table shows molecular features associated with FMR1NB in patient tissues and cancer cell lines. In patient samples, FMR1NB shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FMR1NB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
